ArticleCureus2025

Successful Sequential Use of the Antibody-Drug Conjugate Trastuzumab Deruxtecan After Progression on Sacituzumab Govitecan in a Recurrent Treatment-Resistant Ovarian Cancer Patient: A Case Report.

Victoria M Ettorre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.